pyrazines has been researched along with alendronate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gryczynski, Z; Ranjan, AP; Raut, SL; Thamake, SI; Vishwanatha, JK | 1 |
| Baron, R; Basto, P; Bertrand, N; Farokhzad, OC; Ghobrial, IM; Glavey, S; Kamaly, N; Liu, J; Lu, ZN; Manier, S; Memarzadeh, M; Mishima, Y; Moschetta, M; Nagano, K; Reagan, MR; Roccaro, AM; Sacco, A; Seevaratnam, D; Shi, J; Swami, A; Wu, J; Zhang, S; Zhang, Y | 1 |
2 other study(ies) available for pyrazines and alendronate
| Article | Year |
|---|---|
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Curcumin; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Osteoporosis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines | 2012 |
Engineered nanomedicine for myeloma and bone microenvironment targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Delivery Systems; Heterografts; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |